The study compared individuals with hepatic steatosis (FLI ≥ 60) to those without (FLI < 30) and found that the OR (95% CI) for a high Framingham 10-year cardiovascular disease (CVD) risk ≥ 10% in individuals with hepatic steatosis was 3.43 (3.01–3.91) before adjustment and 2.56 (1.97–3.33) after adjusting for various factors such as age, gender, blood glucose, cholesterol levels, blood pressure, C-reactive protein, lifestyle factors, and smoking status. The gene discussed is CRP; the disease is fatty liver disease.